Further Information
Bcl-2 Antibody: Bcl-2, PPP1R50, Apoptosis regulator Bcl-2
ELISA: order BSA-free format for coating
Flow Cytometry: 0.5-1 ug/million cells
IF: 0.5-1 ug/ml
WB: 0.5-1 ug/ml
IHC (FFPE): 0.5-1 ug/ml for 30 minutes at RT (1)
The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the antibody to be titered up or down for optimal performance.
1. Staining of formalin-fixed tissues is enhanced by boiling tissue sections in 1mM EDTA Buffer, pH 7.5-8.5, for 10-20 min followed by cooling at RT for 20 minutes.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
This antibody recognizes a protein of 25-26kDa, identified as the Bcl-2 alpha oncoprotein. It shows no cross-reaction with Bcl-x or Bax protein. Expression of Bcl-2 alpha oncoprotein inhibits the programmed cell death (apoptosis). In most follicular lymphomas, neoplastic germinal centers express high levels of Bcl-2 alpha protein, whereas the normal or hyperplastic germinal centers are negative. Consequently, this antibody is valuable when distinguishing between reactive and neoplastic follicular proliferation in lymph node biopsies. It may also be used in distinguishing between those follicular lymphomas that express Bcl-2 protein and the small number in which the neoplastic cells are Bcl-2 negative.
PBS with 0.1 mg/ml BSA and 0.05% sodium azide
0.2 mg/mL
Unconjugated
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
A synthetic peptide, aa 41-54 (GAAPAPGIFSSQPG-Cys) of human Bcl-2 protein was used as the immunogen for this antibody.
596
B-cell CLL/lymphoma 2
BCL2
Homo sapiens
Liquid
Protein G affinity chromatography
Apoptosis,Autophagy,Cancer
Does not react with mouse and rat
P10415
Optimal dilutions for each application to be determined by the researcher